Follow-up of two randomised trials in 526 girls given two quadrivalent HPV doses at ages 9-10: all had detectable HPV16/18 antibodies at 10 years; an additional dose at 42 or 60 months gave similar, higher antibody levels than two doses alone.
RCTn = 526
Sauvageau et al. Long-term immunogenicity of alternative HPV vaccine schedules and the effect of an additional dose given three to five years post-primary vaccination